This Prime Day The Pixel 9 Pro Fold Is $415 Off, a New Record Low
In our review of the Pixel 9 Pro Fold, mobile expert Lisa Eadicicco stated that the device is "more polished and practical" in terms of design than its predecessor, feeling like "a big leap" forward. As well as the improved physical form, she praised its larger screens and the substantial seven-year software update commitment Google has made for this model. One major issue was the price, but a $415 Prime Day discount goes a long way toward addressing that.
Hey, did you know? CNET Deals texts are free, easy and save you money.
The price reduction here makes this one of the best Google Pixel deals around for anyone not looking to trade an old phone in or get a new line. It's a very solid discount.
Why this deal matters
Google's foldable phone is the most expensive in the lineup, meaning tech fans have to pay a premium to get one. With this deal, the price is cut substantially, matching the all-time low we saw for the device during the pre-holiday shopping season. It's the most affordable way to get the Pixel 9 Pro Fold right now without a carrier contract.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
Prediction: This Artificial Intelligence (AI) Stock Could Hit a $2 Trillion Valuation by July 31
Key Points Meta Platforms' recent rally has brought its market cap close to the $2 trillion mark. The digital advertising giant's upcoming earnings report could help it hit this milestone. Meta's ability to deliver strong returns to advertisers with the help of AI tools could help it grow at a faster pace than the end market in the long run, paving the way for more upside. These 10 stocks could mint the next wave of millionaires › Meta Platforms (NASDAQ: META) stock has been rallying impressively of late, gaining more than 32% in the past three months amid the broader rally in technology stocks. As a result, Meta's market cap has jumped to $1.8 trillion as of this writing on July 14, making it the sixth-largest company in the world. Meta is slated to release its second-quarter results after the market closes on July 31. The company has been able to grow at a faster pace than the digital ad market thanks to the integration of artificial intelligence (AI) tools into its offerings, which could enable it to deliver another solid set of results later this month. Given that Meta stock is just 11% away from entering the $2 trillion market cap club as I write this, there is a good chance it could achieve that milestone in July, driven by the tech stock rally and a healthy quarterly report. Let's look at the reasons why Meta stock is primed for more upside this month and in the long run. Meta Platforms can exceed expectations once again It is worth noting that Meta's earnings have been better than consensus expectations in each of the last four quarters. One reason is the increase in spending across its family of applications by advertisers. In the first quarter, for instance, Meta reported an impressive increase of 10% year over year in the average price per ad. Ad impressions also increased by 5% from the year-ago period, which means the company is delivering more ads. This combination of higher pricing per ad and an increase in impressions delivered enabled Meta to report a 37% year-over-year increase in its earnings to $6.43 per share in Q1. However, investors should also note that the company has been aggressively increasing its capital expenditures (capex) to bolster its AI infrastructure. It expects to spend $68 billion on capex in 2025, at the midpoint of its guidance range. That would be a massive increase over its 2024 capex of $39 billion. This explains why analysts are expecting Meta's earnings to increase at a slower year-over-year pace of 13% for the second quarter to $5.84 per share. While the increased investment in AI-focused data center infrastructure is undoubtedly likely to weigh on Meta's bottom line in the short run, the higher returns its AI investments are generating on the advertising front could help it beat the market's bottom-line expectations. And beating expectations often sends a stock up, as investors react with excitement and optimism. Meta management points out that users are now spending more time on its applications thanks to AI-recommended content. In the six months that ended March 31, Meta saw the time spent on Facebook and Instagram increase by 7% and 6%, respectively. The increase in user engagement tells us why it has been able to serve more ads. Moreover, the gains advertisers have seen on the dollars they are spending on Meta's applications are also quite solid. A couple of months ago, Meta said it "assessed the impact of [its] new AI-driven advertising tools and found that they drive a 22% improvement in return on ad spend for advertisers. This means that for every dollar U.S. advertisers spend with Meta, they see a $4.52 return when they use [its] new AI-driven advertising tools." Unsurprisingly, Meta saw a 30% increase in the number of advertisers using its AI tools to create campaigns in the first quarter. So, there is indeed a solid possibility that Meta will clock healthy growth in ads delivered and the average price per ad in Q2, which could pave the way for a better-than-expected jump in its bottom line and help the company cross the $2 trillion milestone. I expect it to hit that market cap before Aug. 1. The long-term picture is bright as well Looking ahead, Meta expects that it will allow advertisers to completely automate the creation and execution of ad campaigns by the end of next year. As such, there is a good chance that Meta's earnings growth could accelerate from 2026, following this year's projected increase of 7%. Estimates are shown in the chart below. However, there is a strong possibility that Meta's earnings growth will outpace market expectations, thanks to AI. That's why it won't be surprising to see its market cap jumping to higher levels in the long run, as the digital ad market is expected to clock a robust annual growth rate of 15% through 2030, and Meta has the ability to keep growing at a faster pace than the end market. Don't miss this second chance at a potentially lucrative opportunity Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $447,134!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $40,090!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $652,133!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join , and there may not be another chance like this anytime soon.*Stock Advisor returns as of July 14, 2025 Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Harsh Chauhan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Meta Platforms. The Motley Fool has a disclosure policy. Prediction: This Artificial Intelligence (AI) Stock Could Hit a $2 Trillion Valuation by July 31 was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a minute ago
- Yahoo
A Once-in-a-Lifetime Opportunity: This Blue Chip Healthcare Stock Down 50% Could Double Your Money
Key Points Novo Nordisk's recent financial results and clinical progress haven't impressed Wall Street. However, the company can right the ship through innovation in its core specialty and elsewhere. The stock looks attractively valued at current levels and could beat the market over the next six years. 10 stocks we like better than Novo Nordisk › Investors looking to strike while the iron is hot can buy beaten-down stocks that appear to have excellent chances of bouncing back. And that describes shares of Novo Nordisk (NYSE: NVO) very well. The pharmaceutical leader is down by 52% over the trailing-12-month period as of July 17, but initiating a position now could double investors' money in six years or so. Here's why this stock is a screaming buy at its current levels. Novo Nordisk's recent challenges Novo Nordisk focuses on developing diabetes treatments, an area where it has been a leader for many decades. As of February, it held a 33.3% market share for diabetes drugs. This sort of long-term dominance doesn't happen by accident. The company has consistently attracted top talent in the pharmaceutical industry, which, combined with its extensive experience in diabetes, has enabled it to break new ground repeatedly. Why, then, have the company's shares dropped by 52% over the past year? Because Novo Nordisk failed to impress the market with its financial results and clinical progress. The developments that led to the drugmaker's share plunge would have been excellent for almost any other pharmaceutical company, but investors held it to a higher standard given its rich valuation metrics. For instance, the company reported phase 3 results for CagriSema, an investigational weight management medicine, that proved it's more effective than its famous semaglutide (Wegovy), reducing patients' weight by an average of 22.7% in 68 weeks. However, management was looking for a 25% figure in the study. Very few anti-obesity therapies in development have achieved results comparable to CagriSema, but that was not enough to please investors. The good news: Novo Nordisk's pipeline in diabetes and the fast-growing area of weight management remains robust. The company has several promising candidates in development, including Amycretin, for which it recently initiated late-stage studies. And management has significantly expanded its pipeline through acquisitions. Even with mounting competition, the company should continue to be one of the leaders in its core areas of focus. It's been developing medicines in other fields as well, including various rare diseases (such as the blood disorders beta thalassemia and sickle cell disease), neurological disorders (including Alzheimer's and Parkinson's), and others. Making progress in diabetes and obesity while diversifying its lineup should work wonders for Novo Nordisk down the line. The price is right Net sales in the first quarter grew by 19% year over year to 78.1 billion Danish krone ($12.1 billion). The company's net profit was up 14% year over year to $4.5 billion. These would be excellent results for most similarly sized drugmakers, yet Wall Street remains unimpressed. In my view, that has created a wonderful opportunity to buy shares on the dip. The company's forward price-to-earnings ratio (P/E) has declined significantly over the past year and now stands at 16.9, barely above the healthcare industry's 16.2 and lower than the S&P 500's 22.3. But given Novo Nordisk's still excellent position in its core markets of diabetes and obesity treatments -- the latter of which should grow rapidly in the coming years -- and the company's better-than-average revenue and earnings growth, its stock is arguably worth a steeper premium. In fact, the forward P/E is about as low as it has been in over two years. At current levels, shares look like a steal. Here is how things could evolve for the company in the next six years. First, it could make significant clinical and regulatory progress and launch at least one -- if not several -- blockbuster weight loss or diabetes medications. Second, the company should continue recording strong results, with revenue and earnings moving in the right direction. Lastly, it looks likely to continue increasing its dividend, which it has done significantly over the past half-decade. The stock needs a compound annual growth rate of 12.2% to double in the next six years. Novo Nordisk can pull it off, especially for those who opt to reinvest the dividend. Should you buy stock in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 Prosper Junior Bakiny has positions in Novo Nordisk. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. A Once-in-a-Lifetime Opportunity: This Blue Chip Healthcare Stock Down 50% Could Double Your Money was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a minute ago
- Yahoo
You Have $1,000 to Invest. Should You Buy GOOG or GOOGL?
Key Points Alphabet offers investors exposure to powerful tech megatrends like artificial intelligence (AI), cybersecurity, and autonomous transportation -- all under one roof. Alphabet trades under two ticker symbols, but they both represent the same underlying business. Unless voting rights are important to you, either ticker is a great way to invest in this "Magnificent Seven" stock. 10 stocks we like better than Alphabet › The "Magnificent Seven" is a popular tag for the most dominant, high-performing tech companies on the planet. Alphabet (NASDAQ: GOOGL), (NASDAQ: GOOG), Amazon, Apple, Meta Platforms, Microsoft, Nvidia, and Tesla have delivered market-crushing returns over the past decade, in large part because their businesses are on the forefront of the most disruptive technology macrotrends in modern history. While all seven companies are juggernauts in their own right, one Magnificent Seven stock stands out due to its dominant core business, exposure to multiple megatrends, and attractive valuation relative to its cohorts. That stock is Alphabet. An unconventional company There's something else that makes Alphabet different. Unlike the other members of the Magnificent Seven, Alphabet trades under two tickers: GOOG and GOOGL. Why would Alphabet do that? A little history will provide some helpful context. Larry Page and Sergey Brin founded Google (Alphabet's predecessor) in 1998. When Google filed its IPO paperwork in 2004, Page declared in a letter to prospective shareholders: "Google is not a conventional company. We do not intend to become one." In that same letter, Page fretted that becoming a public company could undermine the independence and creative spirit that had been critical to Google's success. He also made it clear that the company would not "shy away from high-risk, high-reward projects" just to hit some arbitrary quarterly financial target. To ensure that Page, Brin, and the rest of the executive team would retain "control over the company's decisions and fate," Google implemented a dual-class stock structure. It's all about insider control Common stock represents partial ownership in a company, and it usually comes with the right to vote on issues such as executive compensation, board members, and mergers and acquisitions. When Google debuted as a publicly traded company in August 2004, it used the dual class structure to concentrate 99% of the voting power in the hands of its founders, executives, and board members. Here's how: Each share of Class A common stock (available to regular investors) came with one vote. Each share of Class B common stock (held by founders and insiders) came with 10 votes. At the time, Page acknowledged that this was an unconventional move for a tech company, although it wasn't uncommon for other types of businesses. Perhaps the most well-known example is Berkshire Hathaway. However, in the years since Google's 2004 IPO, a number of tech companies have adopted dual class structures to maintain insider control, including Meta Platforms, Palantir, and Roblox. . This is where it gets a little confusing In April 2014, Google added another layer of complexity to its share structure by way of a 2-for-1 stock split. On April 2, 2014, Google's shareholders received one share of newly issued Class C stock for every share of Class A stock that they already owned. Starting on April 3, 2014, two classes of Google stock were available to the public: Class A shares (GOOGL): One vote per share Class C shares (GOOG): No voting power The important thing to note is the Class C shares don't come with voting rights. That was the whole point of the 2014 stock split. By issuing nonvoting Class C shares, Google could fund acquisitions and offer stock-based compensation and incentives without diluting executives' voting power. To recap, this is the share structure that exists today: Class A shares (GOOGL): One vote per share Class B shares (held by insiders): 10 votes per share Class C shares (GOOG): No voting power Should you buy GOOG or GOOGL? Today, Google the search engine is just one piece of Alphabet, the umbrella company formed in 2015. What makes Alphabet such a compelling investment is that it's not just a search-engine provider. Owning Alphabet is a bit like owning an ETF with exposure to some of the biggest themes in tech -- from cloud computing and AI to autonomous vehicles, cybersecurity, and streaming. And as I alluded to earlier, Alphabet trades at a discount to its Magnificent Seven cohorts based on its forward price-to-earnings (P/E) ratio: But there's still one question left to answer: Is GOOG or GOOGL the better investment? Because GOOGL comes with voting rights, you'd think it would trade at a premium to its Class C sibling, GOOG. But interestingly enough, GOOG has outperformed GOOGL since April 3, 2014, ever-so-slightly: As of July 16, GOOG was priced at $183.77, just a hair above GOOGL at $182.97. So based on the recent price action, you could look at it this way: GOOGL gives you the same exposure to Alphabet's basket of businesses, but at a slightly lower price, with the added benefit of voting power. In reality, most regular investors can't purchase enough shares to have any meaningful impact on the company's strategic direction through their votes. And because both tickers represent the same underlying security, there likely will never be any wide variation in price between the two. So unless you care deeply about voting rights, either ticker is a great way to invest in this Magnificent Seven standout. Should you buy stock in Alphabet right now? Before you buy stock in Alphabet, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Alphabet wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Josh Cable has positions in Alphabet, Amazon, Berkshire Hathaway, Microsoft, Nvidia, and Palantir Technologies. The Motley Fool has positions in and recommends Alphabet, Amazon, Apple, Berkshire Hathaway, Meta Platforms, Microsoft, Nvidia, Palantir Technologies, Roblox, and Tesla. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. You Have $1,000 to Invest. Should You Buy GOOG or GOOGL? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
